Since the beginning of April, EOSS Technologies has become the largest shareholder in the Austrian pharmaceuticals producer Sanochemia Pharmazeutika, holding roughly 50% of the shares.
Following intensive negotiations, a consortium consisting of EOSS, b.e. imaging and Burgenland’s business development agency WiBuG has now been awarded the contract for the purchase of the company via a carve-out. Under the terms of this transaction, significant parts of the business of Sanochemia Pharmazeutika AG have been transferred to a new entity, Sanochemia Pharmazeutika GmbH based in Neufeld an der Leitha. The financial difficulties of the pharmaceutical company, which has been listed on the stock exchange until recently, are thus history.
“We’re boarding here at a renowned company that’s been hit by a storm. Our goal is calm waters – and the development of an innovative, technologically pioneering Austrian leading company.”Thomas Erkinger, CEO EOSS
The acquisition is an important strategic enlargement of EOSS’ life science & med-tech division. By expanding the Austrian production capacities for pharmaceuticals, an important contribution to security of supply within Austria is to be made in the future.
Contact: Kerstin Schanda Corporate Communications +43 664 819 3022 Kerstin.email@example.com